FDA And EMEA Grant Orphan Drug Designation For Antisense Pharma's Investigational Drug Trabedersen In Pancreatic Carcinoma

The biopharmaceutical company Antisense Pharma GmbH has announced that it has received orphan drug designation from both the European Medicines Agency EMEA and the US Food and Drug Administration FDA for its investigational drug trabedersen in the treatment of pancreatic carcinoma.